PCR

Liquid Biopsy Global Market Report 2022: Cancer Awareness Initiatives Undertaken by Global Health Organizations Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

Market growth is driven by factors such as rising global prevalence of cancers and the growing need for early detection coupled with efficient treatment monitoring and recurrence detection is anticipated to support the growth of the global liquid biopsy market.

Key Points: 
  • Market growth is driven by factors such as rising global prevalence of cancers and the growing need for early detection coupled with efficient treatment monitoring and recurrence detection is anticipated to support the growth of the global liquid biopsy market.
  • The assay kits segment accounted for the highest growth rate in the liquid biopsy market, by product & service, during the forecast period
    The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service.
  • In 2021, the assay kits segment accounted for the highest growth rate in the liquid biopsy market.
  • The global liquid biopsy market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.

Global Life Science Instrumentation Market to Reach $79.8 Billion by 2027 at a CAGR of 4.8% - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

In the changed post COVID-19 business landscape, the global market for Life Science Instrumentation estimated at US$58.2 Billion in the year 2020, is projected to reach a revised size of US$79.8 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027.

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Life Science Instrumentation estimated at US$58.2 Billion in the year 2020, is projected to reach a revised size of US$79.8 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027.
  • Spectroscopy, one of the segments analyzed in the report, is projected to record a 4.8% CAGR and reach US$19.2 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $16.9 Billion, While China is Forecast to Grow at 4.2% CAGR
    The Life Science Instrumentation market in the U.S. is estimated at US$16.9 Billion in the year 2020.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027.

Global Cancer/Tumor Profiling Market Report 2022: Technological Advancements in Cancer Profiling Techniques Boosting Sector

Retrieved on: 
Friday, December 2, 2022

The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period.

Key Points: 
  • The global cancer/tumor profiling market is projected to reach USD 16.0 Billion by 2027 from USD 9.7 Billion in 2022, at a CAGR of 10.6% during the forecast period.
  • Growth in this market is majorly driven by rising funding investments in cancer research and technological advancements in profiling technologies.
  • Based on cancer type, the cancer/tumor profiling market has been segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancers.
  • Based on biomarker type, the global cancer/tumor profiling market is segmented into genomic and protein biomarkers.

IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages

Retrieved on: 
Thursday, December 1, 2022

PLACCINE is IMUNONs non-viral, non-device plasmid DNA-based vaccine modality targeting multiple antigens from a single vector.

Key Points: 
  • PLACCINE is IMUNONs non-viral, non-device plasmid DNA-based vaccine modality targeting multiple antigens from a single vector.
  • In addition, the data presented showed that IMUNONs plasmid DNA vaccine yielded comparable yet more durable antigen expression than either the protein or a commercial mRNA vaccine.
  • We are delighted to share preclinical proof of concept along with highlighting key competitive advantages to a global audience of vaccine and immunotherapy leaders, said Dr. Corrine Le Goff, IMUNONs President and Chief Executive Officer.
  • IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

New England Biolabs® Introduces NEB Lyophilization Sciences™, Ltd.

Retrieved on: 
Thursday, December 1, 2022

IPSWICH, Mass., Dec. 1, 2022 /PRNewswire/ -- New England Biolabs (NEB®), a leading supplier of life science reagents, introduces New England Biolabs Lyophilization Sciences (NEB Lyo Sciences™) – a wholly owned subsidiary of NEB with expertise in the design, development and manufacturing of innovative solutions for ambient stored products.

Key Points: 
  • IPSWICH, Mass., Dec. 1, 2022 /PRNewswire/ -- New England Biolabs (NEB), a leading supplier of life science reagents, introduces New England Biolabs Lyophilization Sciences (NEB Lyo Sciences) a wholly owned subsidiary of NEB with expertise in the design, development and manufacturing of innovative solutions for ambient stored products.
  • In May 2021, NEB acquired Fluorogenics Limited (FGL), facilitating the combination of NEB's expertise in enzymology with FGL's extensive understanding of the lyophilization process.
  • NEB will continue to incorporate the capabilities of NEB Lyo Sciences into its existing OEM and Customized Solutions business, expanding the services that it offers.
  • NEW ENGLAND BIOLABSand NEBare registered trademarks of New England Biolabs, Inc.
    NEW ENGLAND BIOLABS LYOPHILIZATION SCIENCES, NEB LYO SCIENCES and LYOPRIME are trademarks of New England Biolabs, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/new-england-biolabs-introduces-...

Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market

Retrieved on: 
Thursday, December 1, 2022

MINNEAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening. Asuragen will leverage its gold-standard PCR technology with Oxford Nanopore's any-read-length DNA sequencing capabilities to develop the first sequencing system to identify the most challenging yet high prevalence carrier genes in a single, unified workstream that today requires multiple other methods.

Key Points: 
  • MINNEAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Asuragen,a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.
  • Carrier screening identifies at-risk-couples (ARCs) with pathogenic variants associated with severe genetic disorders.
  • This information can be used to determine the residual risk for passing on a condition to their children and help guide reproductive decision-making.
  • "We are really pleased to be working with Asuragen to develop more robust, reliable and accessible options for reproductive health and carrier screening," said Gordon Sanghera, Chief Executive Officer of Oxford Nanopore Technologies.

COVID-19 Patients Show Liver Injury Months After Infection

Retrieved on: 
Thursday, December 1, 2022

Over time, healthy liver tissue diminishes, and the liver can no longer function properly.

Key Points: 
  • Over time, healthy liver tissue diminishes, and the liver can no longer function properly.
  • In the retrospective study, the researchers compared liver stiffness of patients with a history of COVID-19 infection to two control groups.
  • After controlling for age, sex and time period, a statistical analysis of the elastography results revealed that COVID-positive patients had a statistically significant higher liver stiffness than the control patients.
  • "We don't yet know if elevated liver stiffness observed after COVID-19 infection will lead to adverse patient outcomes," Dr. Heidari said.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

DNA ConneXions® Raising Awareness for Alzheimer's Disease

Retrieved on: 
Wednesday, November 30, 2022

While the optimal genotype for removing heavy metals is ApoE2/2, ApoE 3/3 is the most common, and the most detrimental genotype is ApoE4/4.

Key Points: 
  • While the optimal genotype for removing heavy metals is ApoE2/2, ApoE 3/3 is the most common, and the most detrimental genotype is ApoE4/4.
  • Individuals with ApoE3/4 or 4/4 have a very difficult time detoxifying mercury or other heavy metals and have an increased propensity to develop Alzheimer's disease.
  • Dr. Blanche Grube, owner/CEO of DNA ConneXions and a dentist for over 40 years stated, "Evidence-based research has linked exposure to mercury dental amalgams as a significant risk factor for Alzheimer's disease.
  • www.dnaconnexions.com
    In support of Alzheimer's disease month, DNA ConneXions is offering a 15% discount on our ApoETest.